These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 20617358

  • 1. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study.
    Nishimoto N, Takagi N.
    Mod Rheumatol; 2010 Dec; 20(6):539-47. PubMed ID: 20617358
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS, Aletaha D.
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [Abstract] [Full Text] [Related]

  • 3. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
    Tuckwell K, Gabay C, Sornasse T, Laubender RP, Wang J, Townsend MJ.
    Adv Rheumatol; 2019 Dec 04; 59(1):54. PubMed ID: 31801637
    [Abstract] [Full Text] [Related]

  • 4. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
    Morris NT, Brook J, Ben-Artzi A, Martin W, Kermani TA, Avedikian-Tatosyan L, Karpouzas G, Nagam H, Navarro G, Choi S, Taylor MB, Elashoff D, Kaeley GS, Ranganath VK.
    Clin Rheumatol; 2021 Dec 04; 40(12):5055-5065. PubMed ID: 34269927
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
    Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.
    Arthritis Res Ther; 2013 Sep 25; 15(5):R135. PubMed ID: 24286472
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Sáez I, Unnebrink K, Kary S, Kupper H.
    Arthritis Rheum; 2008 Jan 15; 59(1):32-41. PubMed ID: 18163417
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. American College of Rheumatology/European League Against Rheumatism remission criteria for rheumatoid arthritis maintain reliable performance when evaluated in 44 joints.
    Kaneko Y, Kondo H, Takeuchi T.
    J Rheumatol; 2013 Aug 15; 40(8):1254-8. PubMed ID: 23772077
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, SHINOBI study group.
    Mod Rheumatol; 2018 Jan 15; 28(1):76-84. PubMed ID: 28622048
    [Abstract] [Full Text] [Related]

  • 14. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
    Futó G, Somogyi A, Szekanecz Z.
    Clin Rheumatol; 2014 May 15; 33(5):623-9. PubMed ID: 24599677
    [Abstract] [Full Text] [Related]

  • 15. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, Bananis E.
    Ann Rheum Dis; 2015 Jun 15; 74(6):1132-7. PubMed ID: 25143522
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Schoels M, Alasti F, Smolen JS, Aletaha D.
    Arthritis Res Ther; 2017 Jul 04; 19(1):155. PubMed ID: 28676129
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
    Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K.
    Mod Rheumatol; 2010 Feb 04; 20(1):40-5. PubMed ID: 19802651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.